Biorestorative Therapies Suspends All Orders, Shipments Of ExoCR, BioX Biocosmeceutical Product Lines Effective Immediately, On Aug 7; Conducting Review Of The Documentation, Sourcing, Regulatory Status Associated With Suspended Products; Has Not ...

BioRestorative Therapies, Inc.

BioRestorative Therapies, Inc.

BRTX

0.00

On August 7, 2026, BioRestorative Therapies, Inc. (the "Company") suspended, effective immediately, all orders and shipments of its biocosmeceutical product lines, consisting of its ExoCR products and its BioX products, pending a business review and regulatory assessment. The Company has not made a decision to discontinue these product lines.

 

The Company is conducting a review of the documentation, sourcing, and regulatory status associated with these products.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.